Compare BRT & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRT | IKT |
|---|---|---|
| Founded | 1972 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.2M | 220.5M |
| IPO Year | 1994 | 2020 |
| Metric | BRT | IKT |
|---|---|---|
| Price | $14.10 | $2.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $19.75 | $5.00 |
| AVG Volume (30 Days) | 33.3K | ★ 945.6K |
| Earning Date | 05-08-2026 | 03-26-2026 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | N/A | ★ 57.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $97,028,000.00 | N/A |
| Revenue This Year | $3.82 | N/A |
| Revenue Next Year | $5.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $13.18 | $1.33 |
| 52 Week High | $16.69 | $2.53 |
| Indicator | BRT | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 36.65 | 68.09 |
| Support Level | $13.18 | $1.63 |
| Resistance Level | $15.04 | $2.53 |
| Average True Range (ATR) | 0.45 | 0.14 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 19.04 | 92.68 |
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.